Your browser doesn't support javascript.
loading
ABSTRACT
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
Full text: 1 Index: WPRIM Type of study: Clinical_trials / Guideline / Observational_studies Language: En Journal: Intestinal Research Year: 2020 Type: Article
Full text: 1 Index: WPRIM Type of study: Clinical_trials / Guideline / Observational_studies Language: En Journal: Intestinal Research Year: 2020 Type: Article